What do you view as the role for docetaxel+ramucirumab for patients with metastatic NSCLC in light of LUNG-MAP S1800A data?

I still think, at this moment, docetaxel/ramucirumab should be considered standard of care (more below). I would not yet transition to pembro/ram for everyone. A broader issue raised by this trial is whether anti-VEGF drugs, or immunotherapy regimens, alter the efficacy of concurrent or subsequent c...

If a patient has previously received both platinum-doublet chemotherapy and ICI (either concurrently or sequentially) and pembrolizumab/ramucirumab, docetaxel/ramucirumab could be an option to consider as the next-line of treatment, though we need to acknowledge that we can’t directly apply the find...

Docetaxel and ramucirumab is an effective regimen for many patients and could be used as subsequent therapy. We lack data on the combination even after frontline immune checkpoint inhibitor therapy but for those who have good performance status, docetaxel and ramucirumab remains a good option for pa...